ClinicalTrials.gg
CompletedNCT03305731ABLEUpdated Feb 19, 2020Results posted

Activating Behavior for Lasting Engagement After Stroke

An interventional study of Activating Behavior for Lasting Engagement in Stroke, Physical Activity and Sedentary Lifestyle, sponsored by University of Pittsburgh. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-19.

Sponsored by University of Pittsburgh · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Stroke survivors demonstrate high levels of sedentary behavior, placing them at risk for exacerbation of chronic health conditions. This may lead to recurrent stroke. Subtle cognitive impairments are common after stroke and can lead to difficulty self-monitoring and problem solving to overcome barriers to physical activity. Investigators developed the Activating Behavior for Lasting Engagement (ABLE) intervention to promote activity scheduling, self-monitoring, and problem solving activity over the full day. This study examines the effects of the ABLE intervention on sedentary behavior after stroke.

Read the detailed description

The study advisory committee added a dose-matched, no-intervention delayed baseline to the study protocol following initial documentation of this study protocol on clinicaltrials.gov. The purpose of this delayed baseline design was to assess the baseline stability on the primary and secondary outcomes. The addition of this timepoint resulted in a shift of post-intervention timepoints as follows: Baseline 1 (week 1), Baseline 2 (week 6), Post-intervention (week 11), and Follow-up (week 18). Intervention was delivered between Baseline 2 and Post-intervention.

02

Conditions studied

  • Stroke
  • Physical Activity
  • Sedentary Lifestyle
  • Behavior, Health
  • Physical Disability

Keywords

  • Rehabilitation
  • Disability
03

In context

Stroke

8,255 studies on the registry are indexed under Stroke; 2,056 are open to participants now.

This study's enrollment of 21 is below the median of 49 across 6,024 interventional studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

University of Pittsburgh is the lead sponsor of 1,419 studies on the registry; 168 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. diagnosis of ischemic or hemorrhagic stroke
  2. ≥6 months and ≤24 months post-stroke
  3. ≥18 years of age
  4. ambulatory in the community with or without an assistive device (e.g. walker, cane)
  5. self-reported sedentary behavior (≥6 hours/day of sedentary behavior reported using the Sedentary Behavior Questionnaire)
  6. reside within 50 miles of Pittsburgh, Pennsylvania

Exclusion criteria

Exclusion Criteria:

  1. severe aphasia (Boston Diagnostic Aphasia Examination score ≤1)
  2. currently receiving outpatient or home care rehabilitation services (physical therapy, occupational therapy, or speech therapy)
  3. current active cancer treatment
  4. medical history of neurodegenerative disorder (i.e. dementia, Parkinson's disease, multiple sclerosis, Lou Gehrig's disease (ALS), glioblastoma, myasthenia gravis)
  5. current major depressive disorder, psychiatric condition, substance abuse (Patient Health Questionnaire-9, PRIME-MD/MINI)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Activating Behavior for Lasting Engagement

    Participants will engage in the ABLE intervention.

    Behavioral: Activating Behavior for Lasting Engagement

Interventions

  • BehavioralActivating Behavior for Lasting Engagement

    Activating Behavior for Lasting Engagement (ABLE) is a behavioral intervention in which participants learn skills to schedule, self-monitor, and problem solve strategies to overcome barriers to engagement in meaningful daily life activities.

06

What researchers measure

Primary outcomes

  1. Change in Daily Sedentary Time Accumulated in Bouts Greater Than or Equal to 30 Minutes

    Objectively measured sedentary time (ActivPAL)

    Time frame: Baseline (Baseline=computed mean of week 1 and week 6) to 11 weeks

  2. Change in Daily Number of Sedentary Breaks

    Objectively measured sedentary breaks (ActivPAL)

    Time frame: Baseline (Baseline=computed mean of week 1 and week 6) to 11 weeks

Secondary outcomes

  1. Change in Daily Number of Sedentary Breaks

    Objectively measured sedentary breaks (ActivPAL)

    Time frame: Baseline (Baseline=computed mean of week 1 and week 6) to 18 weeks

  2. Change in Daily Sedentary Time Accumulated in Bouts Greater Than or Equal to 30 Minutes

    Objectively measured sedentary time (ActivPAL)

    Time frame: Baseline (Baseline=computed mean of week 1 and week 6) to 18 weeks

  3. Change in Participation

    Client rated participation in meaningful daily life activities using the Stroke Impact Scale - Participation Subscale The Stroke Impact Scale - Participation Subscale is a questionnaire-based measure of community participation. Participants rate their participation in 10 types of activities on a 1 to 5 point Likert-type scale. Scores are converted to a 0 to 100 scale, where low scores indicate low participation.

    Time frame: Baseline (Baseline=computed mean of week 1 and week 6) to 11 weeks

  4. Change in Participation

    Client rated participation in meaningful daily life activities using the Stroke Impact Scale - Participation Subscale The Stroke Impact Scale - Participation Subscale is a questionnaire-based measure of community participation. Participants rate their participation in 10 types of activities on a 1 to 5 point Likert-type scale. Scores are converted to a 0 to 100 scale, where low scores indicate low participation.

    Time frame: Baseline (Baseline=computed mean of week 1 and week 6) to 18 weeks

07

Results

Posted Feb 19, 2020

Participant flow

Participant flow — Overall Study
MilestoneActivating Behavior for Lasting Engagement
Started21
Week 620
Week 1120
Completed20
Not completed1
Withdrew: Protocol violation1

Outcome measures

PrimaryChange in Daily Sedentary Time Accumulated in Bouts Greater Than or Equal to 30 Minutes

Objectively measured sedentary time (ActivPAL)

Time frame:
Baseline (Baseline=computed mean of week 1 and week 6) to 11 weeks
Reported as:
Mean · minutes
Change in Daily Sedentary Time Accumulated in Bouts Greater Than or Equal to 30 Minutes
minutesActivating Behavior for Lasting Engagement
Change in Daily Sedentary Time Accumulated in Bouts Greater Than or Equal to 30 Minutes54.95 ± 81.10
PrimaryChange in Daily Number of Sedentary Breaks

Objectively measured sedentary breaks (ActivPAL)

Time frame:
Baseline (Baseline=computed mean of week 1 and week 6) to 11 weeks
Reported as:
Mean · breaks
Change in Daily Number of Sedentary Breaks
breaksActivating Behavior for Lasting Engagement
Change in Daily Number of Sedentary Breaks2.61 ± 4.59
SecondaryChange in Daily Number of Sedentary Breaks

Objectively measured sedentary breaks (ActivPAL)

Time frame:
Baseline (Baseline=computed mean of week 1 and week 6) to 18 weeks
Reported as:
Mean · breaks
Change in Daily Number of Sedentary Breaks
breaksActivating Behavior for Lasting Engagement
Change in Daily Number of Sedentary Breaks-2.55 ± 5.90
SecondaryChange in Daily Sedentary Time Accumulated in Bouts Greater Than or Equal to 30 Minutes

Objectively measured sedentary time (ActivPAL)

Time frame:
Baseline (Baseline=computed mean of week 1 and week 6) to 18 weeks
Reported as:
Mean · minutes
Change in Daily Sedentary Time Accumulated in Bouts Greater Than or Equal to 30 Minutes
minutesActivating Behavior for Lasting Engagement
Change in Daily Sedentary Time Accumulated in Bouts Greater Than or Equal to 30 Minutes14.08 ± 58.95
SecondaryChange in Participation

Client rated participation in meaningful daily life activities using the Stroke Impact Scale - Participation Subscale The Stroke Impact Scale - Participation Subscale is a questionnaire-based measure of community participation. Participants rate their participation in 10 types of activities on a 1 to 5 point Likert-type scale. Scores are converted to a 0 to 100 scale, where low scores indicate low participation.

Time frame:
Baseline (Baseline=computed mean of week 1 and week 6) to 11 weeks
Reported as:
Mean · score on a scale
Change in Participation
score on a scaleActivating Behavior for Lasting Engagement
Change in Participation1.48 ± 8.52
SecondaryChange in Participation

Client rated participation in meaningful daily life activities using the Stroke Impact Scale - Participation Subscale The Stroke Impact Scale - Participation Subscale is a questionnaire-based measure of community participation. Participants rate their participation in 10 types of activities on a 1 to 5 point Likert-type scale. Scores are converted to a 0 to 100 scale, where low scores indicate low participation.

Time frame:
Baseline (Baseline=computed mean of week 1 and week 6) to 18 weeks
Reported as:
Mean · score on a scale
Change in Participation
score on a scaleActivating Behavior for Lasting Engagement
Change in Participation1.33 ± 15.38

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Activating Behavior for Lasting Engagement0/21 (0%)0/21 (0%)0/21 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Activating Behavior for Lasting Engagement
Mean70.81 ± 10.92
Sex: Female, Male
Sex: Female, Male(Participants)Activating Behavior for Lasting Engagement
Female13
Male8
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Activating Behavior for Lasting Engagement
Hispanic or Latino0
Not Hispanic or Latino21
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Activating Behavior for Lasting Engagement
American Indian or Alaska Native1
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American3
White17
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Activating Behavior for Lasting Engagement
United States21
Stroke Chronicity
Stroke Chronicity(months)Activating Behavior for Lasting Engagement
Mean29.38 ± 14.34
Stroke Type
Stroke Type(Participants)Activating Behavior for Lasting Engagement
Ischemic19
Hemorrhagic2
Stroke Hemisphere
Stroke Hemisphere(Participants)Activating Behavior for Lasting Engagement
Left Hemisphere12
Right Hemisphere7
Both Hemispheres2

1 further baseline measures are reported on the registry.

08

Study locations

1 site
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15260, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Jan 2019, 15 months.

Results were first posted in Feb 2020, 1 year 1 month after primary completion.

Of 3,108 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's 15 months is below that.

Counting every sponsor, half of 3,252 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2017
First posted
Oct 10, 2017
StartActual
Sep 29, 2017
Primary completionActual
Jan 4, 2019
CompletionActual
Jan 4, 2019
Results first posted
Feb 19, 2020
Last update
Feb 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03305731
Responsible party
Emily Kringle (Occupational Therapist, University of Pittsburgh) — Principal investigator
First posted
Oct 10, 2017
Start date
Sep 29, 2017
Primary completion
Jan 4, 2019
Completion
Jan 4, 2019
Results posted
Feb 19, 2020
Last update
Feb 19, 2020

Study contacts

Emily A Kringle, MOT, OTR/L
principal investigator · University of Pittsburgh
Elizabeth R Skidmore, PhD, OTR/L
study chair · University of Pittsburgh

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion